HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Poseida Therapeutics (NASDAQ:PSTX) and maintained a $20 price target.

March 08, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics has been reiterated with a Buy rating and a $20 price target by HC Wainwright & Co. analyst Arthur He.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst could positively influence investor sentiment and potentially lead to a short-term increase in PSTX's stock price. Analyst ratings, especially from well-regarded firms, often impact stock prices as they are seen as endorsements of the company's future prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100